Allergan beats by $0.03, reports revs in-line
Reports Q2 (Jun) earnings of $4.41 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of $4.38; revenues rose 117.5% year/year to $5.73 bln vs the $5.69 bln consensus.
- Total global branded product revenues were $3.7 billion versus $637 million in the prior year quarter. Top key branded product highlights in the quarter included:
- Botox revenues in the second quarter of 2015 were $632 million, driven by continued strong growth in both aesthetic and therapeutic indications.
- Restasis revenues in the second quarter of 2015 were $325 million, following launch of the product's DTC campaign and launch into the primary care marketplace in the quarter.
- "Allergan also recently made the bold decision to divest its generics business to Teva (TEVA) and to streamline its operations with laser sharp focus on its future as a branded Growth Pharma leader."